

# Mirella Giovarelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5935474/publications.pdf>

Version: 2024-02-01

89  
papers

4,566  
citations

81743

39  
h-index

102304

66  
g-index

89  
all docs

89  
docs citations

89  
times ranked

5633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring chitosan-shelled nanobubbles to improve HER2+ immunotherapy via dendritic cell targeting. <i>Drug Delivery and Translational Research</i> , 2022, 12, 2007-2018.	3.0	8
2	Macrophages expressing TREM-1 are involved in the progression of HPV16-related oropharyngeal squamous cell carcinoma. <i>Annals of Medicine</i> , 2021, 53, 541-550.	1.5	3
3	Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 3570.	1.7	9
4	Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1486-1498.	1.6	25
5	Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells <i>in vitro</i> and <i>in vivo</i> on orthotopic xenograft tumors. <i>Drug Delivery</i> , 2017, 24, 670-680.	2.5	41
6	Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. <i>Frontiers in Immunology</i> , 2017, 8, 1097.	2.2	208
7	<i>In Vitro</i> and <i>In Vivo</i> Therapeutic Evaluation of Camptothecin-Encapsulated $\beta$ -Cyclodextrin Nanosponges in Prostate Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 114-127.	0.5	67
8	Regulation of Langerhans cell functions in a hypoxic environment. <i>Journal of Molecular Medicine</i> , 2016, 94, 943-955.	1.7	10
9	Anti- $\alpha$ -enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response. <i>OncolImmunology</i> , 2016, 5, e1112940.	2.1	19
10	Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. <i>Diabetologia</i> , 2016, 59, 325-333.	2.9	139
11	Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. <i>Pancreas</i> , 2014, 43, 1066-1072.	0.5	14
12	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2910-2921.	3.2	24
13	Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. <i>Diabetologia</i> , 2014, 57, 1664-1673.	2.9	119
14	B7h Triggering Inhibits the Migration of Tumor Cell Lines. <i>Journal of Immunology</i> , 2014, 192, 4921-4931.	0.4	40
15	Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and $\beta$ -TREM expression. <i>European Journal of Immunology</i> , 2013, 43, 949-966.	1.6	49
16	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1098-1106.	0.6	104
17	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67.	6.9	42
18	The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. <i>Immunobiology</i> , 2013, 218, 76-89.	0.8	59

#	ARTICLE	IF	CITATIONS
19	Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2013, 190, 1125-1134.	0.4	28
20	Pro-Inflammatory Profile of Preeclamptic Placental Mesenchymal Stromal Cells: New Insights into the Etiopathogenesis of Preeclampsia. <i>PLoS ONE</i> , 2013, 8, e59403.	1.1	59
21	Circulating Autoantibodies to Phosphorylated $\alpha$ -Enolase are a Hallmark of Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 105-112.	1.8	119
22	Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. <i>Blood</i> , 2011, 117, 2625-2639.	0.6	119
23	The interferon-inducible gene IFI16 secretome of endothelial cells drives the early steps of the inflammatory response. <i>European Journal of Immunology</i> , 2010, 40, 2182-2189.	1.6	32
24	Expression of IFN $\gamma$ R2 mutated in a dileucine internalization motif reinstates IFN $\gamma$ signaling and apoptosis in human T lymphocytes. <i>Immunology Letters</i> , 2010, 134, 17-25.	1.1	12
25	Human Mesenchymal Stem Cells Modulate Cellular Immune Response to Islet Antigen Glutamic Acid Decarboxylase in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3788-3797.	1.8	41
26	The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. <i>Journal of Autoimmunity</i> , 2010, 35, 114-123.	3.0	41
27	Survival and Migration of Human Dendritic Cells Are Regulated by an IFN- $\alpha$ -Inducible Axl/Gas6 Pathway. <i>Journal of Immunology</i> , 2009, 183, 3004-3013.	0.4	78
28	An integrated humoral and cellular response is elicited in pancreatic cancer by $\alpha$ -enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. <i>International Journal of Cancer</i> , 2009, 125, 639-648.	2.3	115
29	Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. <i>Immunobiology</i> , 2008, 213, 733-749.	0.8	138
30	Sulfated K5 <i>Escherichia coli</i> Polysaccharide Derivatives as Wide-Range Inhibitors of Genital Types of Human Papillomavirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1374-1381.	1.4	43
31	Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1472-1482.	1.5	88
32	Transcriptome of Hypoxic Immature Dendritic Cells: Modulation of Chemokine/Receptor Expression. <i>Molecular Cancer Research</i> , 2008, 6, 175-185.	1.5	94
33	Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. <i>FASEB Journal</i> , 2008, 22, 2747-2757.	0.2	120
34	Lack of Plasma Protein Hemopexin Dampens Mercury-Induced Autoimmune Response in Mice. <i>Journal of Immunology</i> , 2008, 181, 1937-1947.	0.4	15
35	Activin A Induces Langerhans Cell Differentiation In Vitro and in Human Skin Explants. <i>PLoS ONE</i> , 2008, 3, e3271.	1.1	41
36	Production and function of activin A in human dendritic cells. <i>European Cytokine Network</i> , 2008, 19, 60-8.	1.1	36

#	ARTICLE	IF	CITATIONS
37	In the absence of IGF-1 signaling, IFN- $\hat{I}^3$ suppresses human malignant T-cell growth. <i>Blood</i> , 2007, 109, 2496-2504.	0.6	20
38	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. <i>Journal of Proteome Research</i> , 2007, 6, 4025-4031.	1.8	88
39	Role of dendritic cell-derived CXCL13 in the pathogenesis of <i>Bartonella henselae</i> B-rich granuloma. <i>Blood</i> , 2006, 107, 454-462.	0.6	65
40	CC-Chemokine Ligand 16 Induces a Novel Maturation Program in Human Immature Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2006, 177, 6143-6151.	0.4	21
41	Iron regulates T-lymphocyte sensitivity to the IFN- $\hat{I}^3$ /STAT1 signaling pathway in vitro and in vivo. <i>Blood</i> , 2005, 105, 3214-3221.	0.6	40
42	Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. <i>Journal of Pathology</i> , 2005, 205, 82-91.	2.1	39
43	Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor. <i>Journal of Immunology</i> , 2004, 172, 4026-4036.	0.4	38
44	CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. <i>Journal of Leukocyte Biology</i> , 2004, 75, 135-142.	1.5	37
45	The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. <i>Experimental Cell Research</i> , 2004, 293, 331-345.	1.2	60
46	CCL16 activates an angiogenic program in vascular endothelial cells. <i>Blood</i> , 2004, 103, 40-49.	0.6	85
47	IGF-1 down-regulates IFN- $\hat{I}^3$ R2 chain surface expression and desensitizes IFN- $\hat{I}^3$ /STAT-1 signaling in human T lymphocytes. <i>Blood</i> , 2003, 102, 2933-2939.	0.6	45
48	LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. <i>Cancer Research</i> , 2003, 63, 2518-25.	0.4	67
49	Death Receptor Ligands in Tumors. <i>Journal of Immunotherapy</i> , 2002, 25, 1-15.	1.2	20
50	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142.	0.4	326
51	Tumor Rejection and Immune Memory Elicited by Locally Released LEC Chemokine Are Associated with an Impressive Recruitment of APCs, Lymphocytes, and Granulocytes. <i>Journal of Immunology</i> , 2000, 164, 3200-3206.	0.4	83
52	Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. , 1998, 186, 390-397.		13
53	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596.	4.2	291
54	Cytokines and Tumor Immunogenicity. , 1998, , 231-247.		1

#	ARTICLE	IF	CITATIONS
55	Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1049-1058.	3.0	158
56	Cytokines, tumour-cell death and immunogenicity: a question of choice. <i>Trends in Immunology</i> , 1997, 18, 32-36.	7.5	161
57	Inhibition of tumor growth and enhancement of metastasis after transfection of the $\hat{I}^3$ -interferon gene. <i>International Journal of Cancer</i> , 1993, 55, 320-329.	2.3	89
58	Modulation of interferon- $\hat{I}^3$ receptor during human T lymphocyte alloactivation. <i>European Journal of Immunology</i> , 1993, 23, 1226-1231.	1.6	14
59	Tumor Immunogenicity Induced by the Local Occurrence of Il-2. , 1993, , 31-37.		0
60	Strategies for cytokine utilisation in tumor therapy. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1993, 10, 53-59.	1.0	6
61	Tumour Immunogenicity Induced by Exogenous Interleukins. , 1992, , 29-35.		0
62	Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. <i>Head and Neck</i> , 1991, 13, 125-131.	0.9	50
63	Interleukin 2: In Vivo Induction of Effector Cells. , 1990, , 37-46.		0
64	Lymphokine-activated tumor inhibition: Combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon- $\hat{I}^3$ injected around tumor-draining lymph nodes. <i>International Journal of Cancer</i> , 1989, 44, 62-65.	2.3	10
65	B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. <i>Journal of Clinical Immunology</i> , 1989, 9, 329-337.	2.0	4
66	Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of Interleukin-2 injected perilymphatically. <i>Cancer</i> , 1988, 62, 2482-2485.	2.0	146
67	Interferon- $\hat{I}^3$ is not an antiviral, but a growth-promoting factor for t lymphocytes. <i>European Journal of Immunology</i> , 1988, 18, 503-510.	1.6	59
68	Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. <i>Cancer and Metastasis Reviews</i> , 1988, 7, 289-309.	2.7	59
69	Release of interleukin-2-like material by b-chronic lymphocytic leukemia cells. An autocrine or paracrine model of production and utilization?. <i>Leukemia Research</i> , 1988, 12, 201-209.	0.4	9
70	Tumor Immunotherapy by Local Injection of Interleukin 2 and Non-Reactive Lymphocytes. <i>Progress in Tumor Research</i> , 1988, 32, 187-212.	0.1	29
71	In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39). <i>International Journal of Immunopharmacology</i> , 1987, 9, 659-667.	1.1	6
72	Lymphokine-Activated Tumor Inhibition (LATI) in Vivo. , 1987, , 335-360.		4

#	ARTICLE	IF	CITATIONS
73	Strategies for cell-mediated immunotherapy of cancer: killing or help?. Trends in Immunology, 1986, 7, 202-203.	7.5	12
74	Physiological and pathological influences of central nervous system on the immune system: A critical appraisal. Journal of Psychiatric Research, 1984, 18, 491-499.	1.5	7
75	IL-2 and Lymphocytes from Tumor Bearing Mice: A Combinatory Immunotherapy of Tumors. , 1984, , 159-173.		0
76	Radiofrequency destruction of the tuberoinfundibular region of hypothalamus permanently abrogates NK cell activity in mice. Nature, 1983, 306, 181-184.	13.7	89
77	In Vivo Requirements for the Immune Recognition of L1210 Leukemia Cells by Allogeneic T-Lymphocytes. Tumori, 1983, 69, 403-408.	0.6	0
78	DISTINCT ALLOANTIGENS TRIGGER PROLIFERATIVE OR NONPROLIFERATIVE T LYMPHOCYTE ACTIVATION IN CBA/N, CBA/J, AND C3H MICE. Transplantation, 1982, 33, 260-264.	0.5	6
79	Rous sarcoma virus-induced tumors in miceâ€”I. Macrophage-mediated natural cytotoxicity. European Journal of Cancer & Clinical Oncology, 1982, 18, 307-315.	0.9	5
80	Immune recognition of tumor cells in vivo. I. Role of H-2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells. European Journal of Immunology, 1982, 12, 664-670.	1.6	15
81	Suppressor macrophages in tumor-bearing mice. Inconsistency between in vivo and in vitro findings?. International Journal of Cancer, 1982, 29, 695-698.	2.3	10
82	Evolution of macrophage immune recognition of viral, bacterial, protozoal and allo-antigens. Developmental and Comparative Immunology, 1981, 5, 61-66.	1.0	2
83	The macrophage as the social interconnection within the immune system. Developmental and Comparative Immunology, 1980, 4, 11-19.	1.0	22
84	Enhancement versus tumor resistance induced by different levels of immunodepression in BALB/c mice with protozoan infections. European Journal of Cancer, 1979, 15, 27-33.	1.0	2
85	H-2-restriction and Ia-dependence of the efficient immune recognition of minor histocompatibility antigens in vivo. Immunogenetics, 1979, 9, 199-202.	1.2	18
86	Lymphokine production in mouse mixed lymphocyte reaction (MLR). Immunogenetics, 1979, 9, 245-253.	1.2	23
87	MATCHING FOR HLA-DR ANTIGENS IN RENAL TRANSPLANTATION. Transplantation, 1979, 27, 288-290.	0.5	4
88	Is antibody-dependent cellular cytotoxicity an important mechanism of resistance to tumors in vivo?. Immunochemistry, 1978, 15, 801-805.	1.3	3
89	In vitro arming and blocking activity of sera from BALB/c mice bearing a spontaneous transplantable adenocarcinoma. European Journal of Cancer, 1977, 13, 1217-1223.	1.0	6